Products

physIQ Heart Rhythm and Respiratory Module
physIQ
Cardiology AI
PhysIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from any wearable biosensor using a deep portfolio of FDA-cleared analytics.

See all 1 product →

About physIQ

physIQ is a leading digital health and therapeutics company that leverages artificial intelligence (AI) to provide personalized physiology data analytics. Their FDA-cleared cloud-based platform continuously collects and processes data from wearable biosensors, establishing a unique physiological baseline for each patient. This personalized approach allows for the detection of subtle, clinically meaningful changes in vital signs and other health indicators that deviate from an individual’s norm, rather than relying on population-based averages.

For physicians, this technology offers unprecedented insights into patient health, enabling proactive care delivery. The physIQ platform supports various virtual care models, including post-acute remote patient monitoring/management and Hospital-at-Home programs. It is designed to monitor, analyze, detect, and predict patient decompensation or complications across a wide range of disease states, such as heart failure, cancer, and COPD. By transforming continuous physiological data into actionable clinical insights, physIQ aims to improve patient outcomes, enhance clinical care, and support more efficient clinical trials.

Focus Areas

Digital Medicine AI-based Personalized Physiology Analytics Continuous Wearable Biosensor Data Remote Patient Monitoring (RPM) Decentralized Clinical Trials Digital Biomarkers Virtual Care Models Post-Acute Care Hospital-at-Home Programs Heart Failure Oncology COPD Viral Infections (e.g. COVID-19)

Business Intelligence

Key InvestorsLionBird, Purdue Foundry, 4490 Ventures, Global Health Sciences (GHS) Fund, Quark Venture Inc., GF Securities
PartnershipsJanssen Pharmaceuticals (Johnson & Johnson), Science 37, Purdue University, University of Illinois Hospital and Health Sciences System, Chicago Medical Society, National Institutes of Health (NIH), U.S. Department of Defense, Henry Jackson Foundation for the Advancement of Military Medicine, OncoBay Clinical, Blue Cross and Blue Shield of Illinois
AcquisitionsProlaio (acquired physIQ)
TechnologyEnterprise-ready cloud platform, Personalized Physiology Analytics (PPA), AI-based analytics, Deep Neural Network Technology, Data- and device-agnostic platform, Collects data from wearable biosensors (e.g., ECG, triaxial accelerometers), Processes raw telemetry in the cloud, Generates digital biomarkers, pinpointIQ™ (monitoring solution), accelerateIQ™ (for clinical trials), Digital Twin model
FDA Clearances6+ cleared products (estimated)

What Physicians Need to Know

Digital Medicine & AI Analytics
physIQ leads in digital medicine, leveraging continuous wearable biosensor data and advanced, FDA-cleared AI analytics to generate unprecedented health insights. Their core innovation is creating a 'personalized dynamic baseline' or 'digital twin' for each patient, enabling the detection of subtle, clinically meaningful physiological changes unique to that individual.
Continuous Wearable Biosensor Data
The platform continuously collects and processes vital sign data (e.g., heart rate, respiratory rate, temperature) from a wide range of wearable biosensors, transforming raw data into actionable clinical insights.
Remote Patient Monitoring (RPM) & Virtual Care
physIQ offers a unified platform for virtual care models, including post-acute remote patient monitoring and Hospital-at-Home programs. Their pinpointIQu2122 solution monitors, analyzes, detects, and predicts patient decompensation across various disease states, aiming to prevent emergency room visits and readmissions.
Decentralized Clinical Trials
The company provides an AI-based remote monitoring solution that modernizes clinical trials by enabling virtual study designs. This approach improves patient experience and provides researchers with continuous, real-time data streams and raw data access, addressing challenges like low participation.
Digital Biomarkers
physIQ possesses a robust portfolio of FDA-cleared analytics and digital biomarkers that convert raw biosensor data into valuable clinical insights. They are actively involved in developing and validating new digital biomarkers for various conditions, including viral infections like COVID-19.
Disease State Management
Their personalized insights and predictive analytics are applied across multiple therapeutic areas, including heart failure, oncology, COPD, and viral infections (e.g., COVID-19), to improve patient monitoring, clinical care, and outcomes.
Physician Tip

For physicians, physIQ stands out by enabling a shift from reactive to proactive care. The platform's ability to create a 'digital twin' for each patient means you receive highly personalized insights, allowing for early detection of subtle physiological changes and prediction of patient decompensation days in advance. This capability can significantly reduce hospital readmissions and emergency room visits. The FDA-cleared nature of their AI analytics provides a strong foundation of trust in the clinical validity of the data. Furthermore, by automating continuous monitoring, physIQ reduces the administrative burden, freeing up valuable time for clinicians to focus on critical interventions and patient care. It empowers effective remote patient management and supports innovative virtual care and Hospital-at-Home models, extending your reach and improving patient outcomes outside traditional clinical settings.

physIQ's enterprise-ready cloud platform is designed for scalability and integration. It is device-agnostic, capable of collecting and processing data from a wide variety of wearable biosensors. The platform integrates with existing Electronic Health Record (EHR) systems to provide a comprehensive view of patient health. They also engage in strategic collaborations with pharmaceutical companies (e.g., Janssen Pharmaceuticals) and clinical research organizations (e.g., Science 37) to scale digital medicine applications and enhance clinical trial data collection.

Products by physIQ

1 product in the directory

physIQ Heart Rhythm and Respiratory Module
physIQ
Cardiology AI
PhysIQ is the leader in digital medicine, dedicated to generating unprecedented health insight using continuous wearable biosensor data and advanced analytics. Its industry-leading, enterprise-ready cloud platform continuously collects and processes data from any wearable biosensor using a deep portfolio of FDA-cleared analytics.

What the Web Says

PhysIQ offers an AI-powered healthcare platform for real-time patient monitoring and data analysis, aiming to improve patient outcomes and reduce readmissions. They also operate fitness centers and offer body contouring treatments and a macro tracking app. Reviews for the healthcare platform are limited but generally positive, highlighting its advanced analytics and integration capabilities. However, reviews for their fitness centers and related services are mixed, with some strong criticisms regarding billing and management practices.

Overall: Mixed

Strengths

  • Advanced AI and machine learning for healthcare insights
  • Real-time patient monitoring and personalized health predictions
  • Integration with existing EHR systems
  • Knowledgeable personal trainers at fitness centers
  • Non-invasive and comfortable body contouring treatments with no downtime
  • User-friendly macro tracking app with adaptive fueling

Limitations

  • Inconsistent scheduling and pay for personal trainers
  • Issues with billing practices at fitness centers
  • Poor management and toxic culture reported by some fitness center employees
  • Fitness centers can be crowded and lack cleanliness at times
  • Limited size range and occasional shipping delays for Physiq Apparel
  • Higher price point for Physiq Apparel

Based on reviews from: SoftwareWorld, Reddit, Cartessa Aesthetics, Indeed.com, WorthEPenny, YouTube, Emily Frost Aesthetics, Apple App Store

Last updated: 2026-07-19

Videos

News, demos, and interviews about physIQ.

Loading videos...

Videos load interactively. If none appear, search YouTube for physIQ →

View all on YouTube

Press & Coverage

PR Newswire
Cartessa Aesthetics Unveils PHYSIQ 360, A Revolutionary Non-Invasive Body Contouring Treatment
Cartessa Aesthetics launched PHYSIQ 360, a new non-invasive body contouring treatment that combines laser energy for fat reduction and electrical muscle stimulation. This next-generation technology offers customizable treatment plans to reduce fat and build muscle across various body types.
2024-04
Science 37
Science 37u00ae and PhysIQ Collaborate to Enhance Clinical Trial Data Collected from Connected Devices
Science 37 and physIQ announced a collaboration to improve clinical trial data by using remote biosensors and machine learning, aiming to increase digital biomarkers and generate insights from continuous data streams. This partnership will help accelerate the demonstration of treatment safety and efficacy.
2022-02
Business Wire
physIQ Announces Two New Appointments to Executive Leadership Team to Advance Digital Health Market Commercialization
PhysIQ appointed John Wilson as Senior Vice President and General Manager of Life Sciences and Chris Englerth as Vice President of Marketing to accelerate its commercialization strategy and growth in the digital medicine market.
2022-05
Business Wire
New Executive Appointments Position physIQ for Further Strategic Growth and Market Expansion
PhysIQ announced the promotion of Chris Economos to Senior Vice President of Corporate Development and the appointment of Michael Petrarca as Senior Vice President and General Manager, Life Sciences, to drive revenue growth and expand strategic partnerships.
2021-11
BioSpace
PhysIQ Expands Clinical Leadership Team, Dr. Steve Steinhubl Joins as Chief Medical Officer
Dr. Steve Steinhubl, an expert in digital medicine, joined physIQ as Chief Medical Officer to advance the adoption of the company's AI-based analytics for improved clinical outcomes and reduced costs.
2021-02
Business Wire
PhysIQ Recognized as a 2021 Hottest Health Tech Company
PhysIQ was named one of the Hottest Health Tech Companies in Digital Health for the second consecutive year by the Observer, recognized for its advancements in continuous remote patient monitoring and its impact during the COVID-19 pandemic.
2021-01
Medical Alley
PhysIQ Saw Significant Adoption of Their AI Technology in 2020
PhysIQ experienced significant adoption of its digital medicine platform in 2020, marked by breakthrough studies, partnerships, and an additional FDA clearance, particularly in addressing the COVID-19 pandemic through continuous remote patient monitoring.
2021-01
MPO (Medical Product Outsourcing)
PhysIQ Expands Patent Portfolio for Artificial Intelligence Analytics in Wearables
PhysIQ received two new patent allowances from the U.S. Patent and Trademark Office for its core artificial intelligence analytics in digital medicine, enhancing its platform for clinical markers of health using continuous wearable sensor data.
2020-04

Frequently Asked Questions

physIQ's core technology is an AI-powered digital platform that continuously collects and processes data from wearable biosensors to create a personalized dynamic baseline, or 'digital twin,' for each patient. This personalized physiology analytics platform, including FDA-cleared algorithms, detects subtle deviations from a patient's normal state, enabling early detection of physiological changes that may precede clinical deterioration. By providing proactive, predictive insights, physIQ aims to improve patient monitoring, clinical care, and overall outcomes in digital medicine.
physIQ's platform, including pinpointIQu2122, is designed as a single solution for virtual care models such as post-acute remote patient monitoring/management and Hospital-at-Home programs. It enables clinicians to monitor, analyze, detect, and predict patient decompensation across various disease states, including heart failure, COPD, and oncology, often identifying issues days before traditional methods. This capability supports proactive interventions, aiming to reduce emergency room visits and readmissions.
Yes, physIQ's accelerateIQu2122 platform is specifically designed to support decentralized clinical trials by collecting and analyzing continuous biosensor data from participants. The platform's FDA-cleared analytics and ability to efficiently identify valuable digital measures from biosensors enable the development of novel digital biomarkers. This capability strengthens the ability of research sponsors, like those in collaboration with Science 37 and Janssen Pharmaceuticals, to generate robust data sets and advance clinical event detection.
physIQ focuses on several key disease areas, including Heart Failure, Oncology, COPD, and Viral Infections. Their platform has demonstrated the ability to predict heart failure hospitalization days in advance and has been used in oncology studies to identify biomarkers for adverse reactions to cancer treatments. For viral infections like COVID-19, physIQ has partnered to develop AI-based algorithms for early detection and to monitor high-risk patients and frontline healthcare workers.
physIQ adheres to rigorous regulatory standards, holding multiple FDA 510(k) clearances for its personalized physiology analytics and various algorithms, including those for respiration rate and atrial fibrillation detection. The company's cloud-based platform is designed to securely collect and process raw biosensor data. While specific HIPAA details are not extensively covered in public search results, physIQ emphasizes a secure cloud environment for data analysis and clinical insights.
While specific pricing models are not publicly detailed, digital health solutions often involve subscription or enterprise licensing. physIQ provides an end-to-end solution including its software platform, AI analytics, third-party wearable biosensors, and a mobile device for data transmission, implying a comprehensive service. The company actively pursues partnership strategies, collaborating with pharmaceutical companies like Janssen, CROs such as Science 37, and healthcare systems, to expand the deployment of its platform and integrate its technology into broader ecosystems.
Founded in 2011, physIQ has a solid track record as a pioneer in digital medicine, with its AI-based analytics being FDA-cleared and supported by rigorous clinical studies. The company has secured venture capital funding and expanded its leadership team, demonstrating ongoing growth and investment in its capabilities. Recent insights suggest an acquisition by Prolaio, indicating a strategic move to enhance its connected heart care platform and further solidify its market position as a long-term digital health partner.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.